Development Level

Tbio 129 | 10,625
Tdark 17 | 7,003
Tchem 13 | 1,890

IMPC Term

preweaning lethality, complete... 7 | 633
embryonic lethality prior to o... 3 | 148
embryonic lethality prior to t... 3 | 187
abnormal coat appearance 1 | 25
abnormal embryo size 1 | 112
abnormal spleen morphology 1 | 36
abnormal thoracic vertebrae mo... 1 | 16
decreased circulating calcium ... 1 | 33
decreased circulating glucose ... 1 | 121
decreased circulating glycerol... 1 | 19
decreased fasted circulating g... 1 | 49
decreased heart weight 1 | 44
decreased hemoglobin content 1 | 53
decreased lean body mass 1 | 195
decreased mean corpuscular hem... 1 | 19
decreased mean corpuscular vol... 1 | 50
decreased neutrophil cell numb... 1 | 37
decreased rib number 1 | 59
enlarged heart 1 | 111
enlarged lymph nodes 1 | 27
increased circulating chloride... 1 | 43
increased circulating free fat... 1 | 17
increased circulating glycerol... 1 | 11
increased circulating sodium l... 1 | 71
increased exploration in new e... 1 | 56
increased grip strength 1 | 83
increased mean corpuscular hem... 1 | 93
increased or absent threshold ... 1 | 128
shortened QT interval 1 | 4
small adrenal glands 1 | 15
small spleen 1 | 11

Disease

ovarian cancer 81 | 8,484
lung cancer 57 | 4,466
Multiple myeloma 53 | 1,327
osteosarcoma 46 | 7,933
medulloblastoma, large-cell 42 | 6,234
intraductal papillary-mucinous neoplasm (IPMN) 40 | 3,289
diabetes mellitus 36 | 1,663
psoriasis 29 | 6,685
glioblastoma 28 | 5,572
sonic hedgehog group medulloblastoma 28 | 1,482
Waldenstrons macroglobulinemia 24 | 765
Diamond-Blackfan anemia 23 | 28
acute quadriplegic myopathy 22 | 1,157
intraductal papillary-mucinous adenoma (IPMA) 22 | 2,956
Breast cancer 21 | 3,094
intraductal papillary-mucinous carcinoma (IPMC) 21 | 2,988
atypical teratoid / rhabdoid tumor 20 | 4,369
pancreatic ductal adenocarcinoma liver metastasis 20 | 1,795
oligodendroglioma 19 | 2,849
lung adenocarcinoma 17 | 2,713
Cancer 16 | 2,346
astrocytoma 16 | 1,493
pediatric high grade glioma 16 | 2,712
invasive ductal carcinoma 15 | 2,950
group 3 medulloblastoma 14 | 2,254
pilocytic astrocytoma 14 | 3,086
Anemia, Diamond-Blackfan 13 | 15
cystic fibrosis 13 | 1,665
ependymoma 13 | 2,514
malignant mesothelioma 13 | 3,162
non-small cell lung cancer 13 | 2,798
subependymal giant cell astrocytoma 13 | 2,287
dermatomyositis 12 | 933
primitive neuroectodermal tumor 12 | 3,031
Mammary Neoplasms 10 | 410
Stomach Neoplasms 10 | 282
acute myeloid leukemia 10 | 780
pancreatic cancer 10 | 2,300
colon cancer 9 | 1,475
ulcerative colitis 9 | 2,087
Disease Progression 8 | 125
breast carcinoma 8 | 1,614
glioblastoma multiforme 8 | 347
juvenile dermatomyositis 8 | 1,189
primary pancreatic ductal adenocarcinoma 8 | 1,271
Anemia 7 | 252
Duchenne muscular dystrophy 7 | 602
Pick disease 7 | 1,893
Prostatic Neoplasms 7 | 471
adult high grade glioma 7 | 2,148
inflammatory breast cancer 7 | 404
mucosa-associated lymphoid tissue lymphoma 7 | 480
active Crohn's disease 6 | 918
astrocytic glioma 6 | 2,241
atypical teratoid/rhabdoid tumor 6 | 1,095
group 4 medulloblastoma 6 | 1,875
hereditary spastic paraplegia 6 | 313
posterior fossa group A ependymoma 6 | 1,511
Childhood Ataxia with Central Nervous System Hypomyelinization 5 | 5
Leukodystrophy 5 | 30
OVARIOLEUKODYSTROPHY 5 | 5
interstitial cystitis 5 | 2,299
lung carcinoma 5 | 2,844
pituitary cancer 5 | 1,972
Animal Mammary Neoplasms 4 | 136
Mammary Neoplasms, Experimental 4 | 150
Neoplasm Metastasis 4 | 138
Optic atrophy 4 | 43
Parkinson Disease 4 | 102
Polycystic Ovary Syndrome 4 | 332
Rheumatoid Arthritis 4 | 1,160
Spinocerebellar ataxia type 2 4 | 19
adrenocortical carcinoma 4 | 1,427
cutaneous lupus erythematosus 4 | 1,056
non primary Sjogren syndrome sicca 4 | 840
spina bifida 4 | 1,064
Amyotrophic Lateral Sclerosis 3 | 431
Brain disease 3 | 83
Down syndrome 3 | 548
HIV Infections 3 | 100
IGA Glomerulonephritis 3 | 454
Intellectual disability 3 | 573
Irregular astigmatism 3 | 11
Neoplasm Invasiveness 3 | 127
Pure red-cell aplasia 3 | 4
Renal Cell Carcinoma 3 | 199
Weight Gain 3 | 87
aldosterone-producing adenoma 3 | 664
progressive supranuclear palsy 3 | 674
substance-related disorder 3 | 105
tuberculosis and treatment for 6 months 3 | 686
Alzheimer's disease 2 | 644
Multiple Sclerosis 2 | 498
Type 2 diabetes mellitus 2 | 189
autosomal dominant Emery-Dreifuss muscular dystrophy 2 | 499
hepatocellular carcinoma 2 | 532
medulloblastoma 2 | 1,524
tuberculosis 2 | 1,557
tuberculosis and treatment for 3 months 2 | 327
type II diabetes mellitus and post-ischemic heart failure 2 | 89

Tissue

Blood and immune system 158 | 17,995
Cardiovascular System 158 | 17,958
Digestive Tract 158 | 18,473
Endocrine System 158 | 18,512
Female tissues 158 | 18,647
Liver and Pancreas 158 | 18,136
Male tissues 158 | 17,969
Nervous System 158 | 18,561
Respiratory system 158 | 17,484
Urinary Tract 158 | 18,444
Skin and soft tissues 156 | 18,115

Target Family

Non-IDG 145 | 11,971
Enzyme 14 | 4,146

Reactome Pathway

Translation 159 | 159
Signal Transduction 2,516 | 2,516
Immune System 2,184 | 2,184
Metabolism 2,132 | 2,132
Gene Expression 1,755 | 1,755
Metabolism of proteins 1,545 | 1,545
Innate Immune System 1,376 | 1,376
Signaling by GPCR 1,330 | 1,330
Developmental Biology 1,029 | 1,029
GPCR downstream signaling 1,015 | 1,015
Post-translational protein mod... 1,005 | 1,005
Adaptive Immune System 939 | 939
Disease 856 | 856
Generic Transcription Pathway 852 | 852
Cytokine Signaling in Immune s... 804 | 804
Metabolism of lipids and lipop... 797 | 797
Vesicle-mediated transport 705 | 705
Hemostasis 669 | 669
Transmembrane transport of sma... 669 | 669
Membrane Trafficking 608 | 608
Cell Cycle 573 | 573
Axon guidance 542 | 542
Neutrophil degranulation 542 | 542
Signaling by Interleukins 501 | 501
Cell Cycle, Mitotic 471 | 471
Signalling by NGF 468 | 468
GPCR ligand binding 456 | 456
Gastrin-CREB signalling pathwa... 436 | 436
Class I MHC mediated antigen p... 431 | 431
Olfactory Signaling Pathway 430 | 430
Fc epsilon receptor (FCERI) si... 424 | 424
Cellular responses to stress 416 | 416
DAP12 interactions 410 | 410
Infectious disease 392 | 392
NGF signalling via TRKA from t... 379 | 379
Signaling by Rho GTPases 378 | 378
Signaling by PDGF 368 | 368
Diseases of signal transductio... 360 | 360
Signaling by EGFR 356 | 356
Transcriptional Regulation by ... 356 | 356
Metabolism of amino acids and ... 354 | 354
DAP12 signaling 347 | 347
Downstream signal transduction 344 | 344
Neuronal System 343 | 343
Organelle biogenesis and maint... 334 | 334
Signaling by VEGF 330 | 330
Signaling by SCF-KIT 328 | 328
Class A/1 (Rhodopsin-like rece... 322 | 322
VEGFA-VEGFR2 Pathway 322 | 322
FCERI mediated MAPK activation 317 | 317
Signaling by Insulin receptor 313 | 313
Antigen processing: Ubiquitina... 302 | 302
Extracellular matrix organizat... 292 | 292
Signaling by Type 1 Insulin-li... 291 | 291
Signaling by Wnt 291 | 291
IGF1R signaling cascade 290 | 290
IRS-related events triggered b... 290 | 290
Insulin receptor signalling ca... 289 | 289
Metabolism of carbohydrates 288 | 288
DNA Repair 286 | 286
IRS-mediated signalling 286 | 286
MAPK family signaling cascades 284 | 284
Signaling by the B Cell Recept... 283 | 283
Asparagine N-linked glycosylat... 282 | 282
SLC-mediated transmembrane tra... 280 | 280
Deubiquitination 278 | 278
Interferon Signaling 275 | 275
Platelet activation, signaling... 274 | 274
NCAM signaling for neurite out... 269 | 269
M Phase 267 | 267
Interleukin-3, 5 and GM-CSF si... 263 | 263
RET signaling 262 | 262
Signalling to ERKs 255 | 255
Interleukin-2 signaling 254 | 254
Immunoregulatory interactions ... 252 | 252
VEGFR2 mediated cell prolifera... 250 | 250
RHO GTPase Effectors 249 | 249
Signalling to RAS 248 | 248
Interleukin receptor SHC signa... 247 | 247
G alpha (i) signalling events 245 | 245
Signaling by Leptin 245 | 245
Fatty acid, triacylglycerol, a... 244 | 244
Prolonged ERK activation event... 244 | 244
MAPK1/MAPK3 signaling 243 | 243
Frs2-mediated activation 242 | 242
HIV Infection 242 | 242
ARMS-mediated activation 241 | 241
Signalling to p38 via RIT and ... 241 | 241
Chromatin modifying enzymes 237 | 237
Chromatin organization 237 | 237
GRB2 events in EGFR signaling 237 | 237
RAF/MAP kinase cascade 237 | 237
SHC1 events in EGFR signaling 237 | 237
SOS-mediated signalling 237 | 237
Processing of Capped Intron-Co... 235 | 235
Biological oxidations 215 | 215
Keratinization 213 | 213
Transmission across Chemical S... 210 | 210
rRNA processing 209 | 209
Ion channel transport 204 | 204
Ub-specific processing proteas... 203 | 203

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
60S ribosomal protein L7a RPL7A Tbio Non-IDG -1.66015 45.9 60
60S ribosomal protein L18 RPL18 Tbio Non-IDG -1.73537 50.7 134
Signal recognition particle 9 kDa protein SRP9 Tbio Non-IDG -1.49375 30.2 29
60S ribosomal protein L38 RPL38 Tdark Non-IDG -1.39563 24.2 45
Eukaryotic peptide chain release factor subunit 1 ETF1 Tbio Enzyme -1.69308 48.0 90
Elongation factor 1-beta EEF1B2 Tbio Non-IDG -1.77658 56.5 100
Ubiquitin-60S ribosomal protein L40 UBA52 Tbio Non-IDG -2.21113 124.2 150
40S ribosomal protein S4, Y isoform 1 RPS4Y1 Tbio Non-IDG -1.22796 15.4 118
60S ribosomal protein L8 RPL8 Tbio Non-IDG -1.56871 36.4 182
40S ribosomal protein S3 RPS3 Tbio Non-IDG -2.16121 152.6 207